Sökning: WFRF:(Cabirta A) > Simultaneous Onset ...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04828naa a2201153 4500 | |
001 | oai:prod.swepub.kib.ki.se:151274975 | |
003 | SwePub | |
008 | 240701s2022 | |||||||||||000 ||eng| | |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1512749752 URI |
024 | 7 | a https://doi.org/10.3390/cancers142255302 DOI |
040 | a (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Cattaneo, C4 aut |
245 | 1 0 | a Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey |
264 | c 2022-11-10 | |
264 | 1 | b MDPI AG,c 2022 |
520 | a Background: The outcome of patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 is unknown and there are no specific treatment guidelines. Methods: We describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022. Results: Acute leukaemia and lymphoma were the most frequent HM (35.8% and 35.1%, respectively). Overall, 343 (76.2%) patients received treatment for HM, which was delayed for longer than one month since diagnosis in 57 (16.6%). An overall response rate was observed in 140 (40.8%) patients after the first line of treatment. After a median follow-up of 35 days, overall mortality was 177/450 (39.3%); 30-day mortality was significantly higher in patients not receiving HM treatment (42.1%) than in those receiving treatment (27.4%, p = 0.004), either before and/or after COVID-19, or compared to patients receiving HM treatment at least after COVID-19 (15.2%, p < 0.001). Age, severe/critical COVID-19, ≥2 comorbidities, and lack of HM treatment were independent risk factors for mortality, whereas a lymphocyte count >500/mcl at COVID-19 onset was protective. Conclusions: HM treatment should be delivered as soon as possible for patients with simultaneous diagnosis of COVID-19 and HM requiring immediate therapy. | |
700 | 1 | a Salmanton-Garcia, J4 aut |
700 | 1 | a Marchesi, F4 aut |
700 | 1 | a El-Ashwah, S4 aut |
700 | 1 | a Itri, F4 aut |
700 | 1 | a Weinbergerova, B4 aut |
700 | 1 | a Da Silva, MG4 aut |
700 | 1 | a Dargenio, M4 aut |
700 | 1 | a Davila-Valls, J4 aut |
700 | 1 | a Martin-Perez, S4 aut |
700 | 1 | a Farina, F4 aut |
700 | 1 | a Van Doesum, J4 aut |
700 | 1 | a Valkovic, T4 aut |
700 | 1 | a Besson, C4 aut |
700 | 1 | a Poulsen, CB4 aut |
700 | 1 | a Lopez-Garcia, A4 aut |
700 | 1 | a Zak, P4 aut |
700 | 1 | a Schonlein, M4 aut |
700 | 1 | a Piukovics, K4 aut |
700 | 1 | a Jaksic, O4 aut |
700 | 1 | a Cabirta, A4 aut |
700 | 1 | a Ali, N4 aut |
700 | 1 | a Sili, U4 aut |
700 | 1 | a Fracchiolla, N4 aut |
700 | 1 | a Dragonetti, G4 aut |
700 | 1 | a Adzic-Vukicevic, T4 aut |
700 | 1 | a Marchetti, M4 aut |
700 | 1 | a Machado, M4 aut |
700 | 1 | a Glenthoj, A4 aut |
700 | 1 | a Finizio, O4 aut |
700 | 1 | a Demirkan, F4 aut |
700 | 1 | a Blennow, Ou Karolinska Institutet4 aut |
700 | 1 | a Tisi, MC4 aut |
700 | 1 | a Omrani, AS4 aut |
700 | 1 | a Navratil, M4 aut |
700 | 1 | a Racil, Z4 aut |
700 | 1 | a Novak, J4 aut |
700 | 1 | a Magliano, G4 aut |
700 | 1 | a Jimenez, M4 aut |
700 | 1 | a Garcia-Vidal, C4 aut |
700 | 1 | a Erben, N4 aut |
700 | 1 | a Del Principe, MI4 aut |
700 | 1 | a Buquicchio, C4 aut |
700 | 1 | a Bergantim, R4 aut |
700 | 1 | a Batinic, J4 aut |
700 | 1 | a Al-Khabori, M4 aut |
700 | 1 | a Verga, L4 aut |
700 | 1 | a Szotkowski, T4 aut |
700 | 1 | a Samarkos, M4 aut |
700 | 1 | a Ormazabal-Velez, I4 aut |
700 | 1 | a Meers, S4 aut |
700 | 1 | a Maertens, J4 aut |
700 | 1 | a Pinczes, LI4 aut |
700 | 1 | a Hoenigl, M4 aut |
700 | 1 | a Drgona, L4 aut |
700 | 1 | a Cuccaro, A4 aut |
700 | 1 | a Bilgin, YM4 aut |
700 | 1 | a Aujayeb, A4 aut |
700 | 1 | a Rahimli, L4 aut |
700 | 1 | a Grafe, S4 aut |
700 | 1 | a Sciume, M4 aut |
700 | 1 | a Mladenovic, M4 aut |
700 | 1 | a Colak, GM4 aut |
700 | 1 | a Sacchi, MV4 aut |
700 | 1 | a Nordlander, Au Karolinska Institutet4 aut |
700 | 1 | a Venemyr, CB4 aut |
700 | 1 | a Hanakova, M4 aut |
700 | 1 | a Garcia-Pouton, N4 aut |
700 | 1 | a Emarah, Z4 aut |
700 | 1 | a Zambrotta, GPM4 aut |
700 | 1 | a Rodrigues, RN4 aut |
700 | 1 | a Cordoba, R4 aut |
700 | 1 | a Mendez, GA4 aut |
700 | 1 | a Biernat, MM4 aut |
700 | 1 | a Cornely, OA4 aut |
700 | 1 | a Pagano, L4 aut |
710 | 2 | a Karolinska Institutet4 org |
773 | 0 | t Cancersd : MDPI AGg 14:22q 14:22x 2072-6694 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:151274975 |
856 | 4 8 | u https://doi.org/10.3390/cancers14225530 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy